Stockreport

FDA approves Novartis radioligand therapy Pluvicto® for earlier use before chemotherapy in PSMA-positive metastatic castration-resistant prostate cancer [Yahoo! Finance]

Novartis AG  (NVS) 
Last novartis ag earnings: 4/28 01:00 am Check Earnings Report
US:NYSE Investor Relations: novartis.com/investors
PDF Pluvicto significantly reduced risk of progression or death by 59% and more than doubled median radiographic progression-free survival ( rPFS) vs. change in ARPI in Pha [Read more]